Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232 -

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232
Information type: Randomised controlled trials
Source: Journal of Clinical Oncology
Specialities: Cancers | Paediatric and neonatal medicine
Summary
In this RCT of 2,914 participants high-dose methotrexate was shown to be superior to Capizzi methotrexate: 5-year event-free survival of 79.6% and 75.2% respectively (P = 0.008) in participants aged 1 to 30 years with newly diagnosed high-risk B-acute lymphoblastic leukaemia.
UKMi comment
The high dose methotrexate regimen comprised 2 to 5 g/m2 administered over 24 hours followed by leucovorin rescue, and the Capizzi regimen comprised a lower, escalating doses of intravenous methotrexate of 100 to 300 mg/m2 through short
infusions, without leucovorin rescue, followed by asparaginase.
Related links: